Portfolio company
Adaptam Therapeutics
Country not known yet
Raised
Not known yet
Latest stage
Not known yet
Rounds recorded
Not known yet
Backed by
1 investor
Sectors
About
Adaptam Therapeutics develops antibody-based therapies for solid tumours to treat oncology patients by targeting immunosuppressive myeloid cells.
SourceFunding history · 0
No rounds recorded yet. The agent looks for them over time.
Similar companies
CellmAbs
This biotech company develops monoclonal antibodies and adoptive cell therapies to treat oncology patients with solid tumours.
Nectin Therapeutics
This company develops novel immunotherapeutic antibodies and antibody-drug conjugates for patients with solid and haematological cancers.
Oxford BioTherapeutics
Oxford BioTherapeutics develops targeted antibody-drug conjugates and immuno-oncology therapies for patients with advanced solid tumours through its proprietary proteomic database.
Tacalyx
This company develops antibody-based therapeutics targeting tumour associated carbohydrate antigens for the treatment of solid tumours in cancer patients.
AdoRx Therapeutics
This company develops small-molecule adenosine receptor antagonists for pharmaceutical partners to treat cancer by disrupting immune evasion in the tumour microenvironment.
Theolytics
The company develops oncolytic viral immunotherapies for patients with solid tumours.
Arch Oncology
This biotechnology firm develops antibody therapies to treat patients with solid tumours and hematologic malignancies.
Adcendo ApS
The company develops antibody-drug conjugates to treat patients with advanced solid tumors and cancers that have high unmet medical needs.